Evaluating efficacy of a Unani formulation in melasma.

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of a Unani Formulation in Kalaf (Melasma).

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036582

Enrollment

Registered

2021-09-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Group A:A Unani formulation: Participants will be advised to apply zimad of a Unani formulation on the affected area at night daily. Control Intervention1: Group B:Hydroquinone 4%: Hydr

Eligibility

Inclusion criteria

Inclusion criteria: Participant having single or multiple, symmetrical or asymmetrical brown macules on face, cheeks, nose, forehead, upper lip and chin.

Exclusion criteria

Exclusion criteria: a) Women who are pregnant, and lactating. b) Participant aged 55 years. c) Significant cardiovascular/ pulmonary/ hepatorenal dysfunction. d) Known case of diabetes mellitus, HIV/ AIDS and malignancy. e) Those unwilling to come for regular follow-up for the entire duration of the study and any patients considered not eligible according to the investigatorâ??s discretion during the study.

Design outcomes

Secondary

Measure	Time frame
improvement in quality of life.Timepoint: 8 weeks	—

Primary

Measure	Time frame
25% reduction in MASI score from the baseline after 8 weeks of treatment.Timepoint: 8 Weeks	—

Countries

India

Contacts

Public ContactTatheer fatma

National Research institute of Unani medicine for skin disorders

ccrumnawab@gmail.com8100992044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026